Original Paper

Ophthalmologica

Ophthalmologica 2014;231:80–85 DOI: 10.1159/000356401

Received: July 30, 2013 Accepted after revision: September 5, 2013 Published online: December 13, 2013

Bimonthly Ranibizumab for Neovascular Age-Related Macular Degeneration Salomon Yves Cohen Bertrand Maloberti Franck Fajnkuchen Sylvia Nghiem-Buffet Corinne Delahaye-Mazza Typhaine Grenet Gabriel Quentel Centre Ophtalmologique d’Imagerie et de Laser, Paris, France

Key Words Age-related macular degeneration · Anti-VEGF · Ranibizumab · Bimonthly fixed regimen

Abstract Background/Purpose: Recently, aflibercept was proposed with a protocol of a bimonthly fixed regimen. Our purpose was to evaluate the results of this regimen in patients treated with ranibizumab. Method: We conducted a retrospective analysis of consecutive patients with naïve neovascular age-related macular degeneration treated with a bimonthly fixed regimen of intravitreal injections of ranibizumab after 3 monthly injections. Examination was performed every 4 weeks for 52 weeks, with the possibility of unscheduled rescue injections of ranibizumab. Results: A total of 27 patients, 24 women and 3 men, aged from 68 to 90 years (mean: 81.2) were analyzed; 25 eyes (92.5%) lost